Interleukin-6 correlates with endothelial dysfunction in young post-myocardial infarction patients

Cardiology

Volumn 107, Issue 2, 2007, Pages 111-116

  Eržen, Barbara ^a   Šabovič, Mišo ^a   Šebeštjen, Miran ^a   Keber, Irena ^a   Poredoš, Pavel ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Endothelial dysfunction; Inflammation markers; Interleukin 6; Myocardial infarction

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY RISK; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; INFLAMMATION; INTRAVASCULAR ULTRASOUND; MALE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ADULT; BIOLOGICAL MARKERS; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; VASODILATION;

EID: 33847066999     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094588     Document Type: Article

References (21)

1. Anderson TJ: Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003;8:71-86.
2. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-175.
3. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA: Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-658.
4. Aukrust P, Yndestad A, Waehre T, Gullestad L, Halvorsen B, Damas JK: Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Rev Cardiovasc Ther 2005;3:1111-1124.
5. Koenig W, Rosenson RS: Acute-phase reactants and coronary heart disease. Semin Vasc Med 2002;2:417-428.
6. Piro M, Giubilato G, Pinnelli M, Giordano Sciacca P, Biasucci LM: Endothelium and inflammation. Panminerva Med 2005;47:75-80.
7. Yip HK, Wu CJ, Hang CL, Chang HW, Yang CH, Hsieh YK, Fang CY, Fu M, Yeh KH, Chen MC: Levels and values of inflammatory markers in patients with angina pectoris. Int Heart J 2005;46:571-581.
8. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H: Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003;91:133-136.
9. Blum A, Schneider DJ, Sobel BE, Dauerman HL: Endothelial dysfunction and inflammation after percutaneous coronary intervention. Am J Cardiol 2004;94:1420-1423.
10. Assmann G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Mal'nster (PROCAM) study. Circulation 2002;105:310-315.
11. Kinlay S, Ganz P: Relation between endothelial dysfunction and the acute coronary syndrome: implications for therapy. Am J Cardiol 2000;86:10J-13J.
12. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE: Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995;74:247-253.
13. Ballantyne CM, Nambi V: Markers of inflammation and their clinical significance. Atheroscler Suppl 2005;6:21-29.
14. Chlopicki S, Gryglewski RJ: Angiotensin converting enzyme (ACE) and Hydroxy-MethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharmacol Rep 2005;57(suppl):86-96.
15. Wilson AM, Ryan MC, Boyle AJ: The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006;26;106:291-297.
16. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-1006.
17. Wang P, Ba ZF, Chaudry IE: Administration of tumor necrosis factor alfa in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994;266:H2535-H2541.
18. Yoshizumi M, Perreila MA, Burnett JC, Lee ME: Tumor necrosis factor downregulates an endothelial nitric oxide synthase m RNA by shortening is half life. Circ Res 1993;73:205-209.
19. Bhagt K, Vallance P: Inflammatory cytokines impair endothelium-dependent dilation in human veins in vivo. Circulation 1997;96:3042-3047.
20. Furumoto T, Fujii S, Saito N, Mikami T, Kitabatke A: Relationship between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 2002;42:117-125.
21. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction. Circulation 2000;18:1767-1772.